Intriguingly, inducible knockdown of PFKP significantly increased clonogenic capacity of breast cancer cells against paclitaxel treatment (Fig. 5e), suggesting that suppression of PFKP followed by redirection of glucose flux towards PPP plays an important role in slowing cell growth coupled with therapeutic resistance of cancer cells. The gene discussed is PFKP; the disease is breast carcinoma.